Immunocore Holdings Ltd
$ 36.13
-1.20%
26 Dec - close price
- Market Cap 1,825,664,000 USD
- Current Price $ 36.13
- High / Low $ 36.59 / 36.06
- Stock P/E N/A
- Book Value 7.86
- EPS -0.58
- Next Earning Report 2026-03-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.02 %
- ROE -0.08 %
- 52 Week High 40.71
- 52 Week Low 23.15
About
Immunocore Holdings Limited is a pioneering biotechnology firm headquartered in Abingdon, UK, focused on developing cutting-edge immunotherapies for cancer, infectious diseases, and autoimmune disorders. Utilizing its proprietary T cell receptor platform, the company seeks to bolster the immune response, promising innovative and potentially transformative treatment options that can significantly enhance patient outcomes. With a strong pipeline of clinical trials and strategic collaborations, Immunocore is strategically positioned to become a key player in the dynamic immunotherapy sector, offering substantial growth opportunities for investors.
Analyst Target Price
$63.89
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-06 | 2025-02-26 | 2024-11-05 | 2024-08-08 | 2024-05-08 | 2024-02-28 | 2023-11-07 | 2023-08-10 | 2023-05-10 | 2023-03-01 |
| Reported EPS | -0.0035 | -0.2 | -0.49 | -0.3714 | 0.17 | -0.23 | -0.49 | -32.22 | 4 | -0.37 | -35 | -54 |
| Estimated EPS | -0.24 | -0.18 | -0.36 | -0.1594 | -0.35 | -0.48 | -0.36 | -21.74 | -28.92 | -32.1 | -32.19 | 0.03 |
| Surprise | 0.2365 | -0.02 | -0.13 | -0.212 | 0.52 | 0.25 | -0.13 | -10.48 | 32.92 | 31.73 | -2.81 | -54.03 |
| Surprise Percentage | 98.5417% | -11.1111% | -36.1111% | -132.9987% | 148.5714% | 52.0833% | -36.1111% | -48.2061% | 113.8313% | 98.8474% | -8.7294% | -180100% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-04 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.2054 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IMCR
2025-12-21 08:09:49
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) has received a consensus rating of "Moderate Buy" from twelve brokerages, with an average 12-month price target of $61.00. Institutional investors own 84.5% of the company's stock, and recent quarterly results showed a beat on EPS but a miss on revenue. The company is a clinical-stage biotechnology firm developing immunotherapies for cancer and infectious diseases.
2025-12-15 15:08:56
Hudson Bay Capital Management LP has reduced its stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 12.5%, selling 49,382 shares and retaining 345,952 shares valued at approximately $10.86 million. This adjustment comes as Immunocore reported Q2 EPS of $0.02, exceeding estimates, though revenue of $103.7 million missed expectations despite a 29.2% year-over-year increase. Analysts currently rate Immunocore as a "Moderate Buy" with a consensus target price of $61.00.
2025-12-14 12:10:55
Frazier Life Sciences Management L.P. has significantly increased its stake in Immunocore Holdings PLC (NASDAQ:IMCR) by 27.8%, now owning 384,782 shares valued at approximately $12.07 million. This move comes as Immunocore reported mixed Q2 earnings, beating EPS estimates but missing revenue projections despite strong year-over-year growth. The company maintains a "Moderate Buy" analyst rating and institutional investors hold 84.5% of its stock.
2025-12-14 08:09:45
Eschler Asset Management LLP recently invested $1.26 million in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR), acquiring 40,000 shares. This investment represents 0.9% of their portfolio, making Immunocore their 25th largest holding. The company currently has a market capitalization of $1.86 billion, with hedge funds and institutional investors owning about 84.5% of the stock.
2025-12-13 14:08:23
Bellevue Group AG significantly increased its stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 99.9% in the second quarter, making it their 16th largest holding. Despite missing revenue forecasts, Immunocore posted a positive EPS of $0.02 and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $61.00. Institutional ownership in Immunocore is high at 84.5%, indicating strong investor confidence.
2025-12-13 09:08:23
BVF Inc. IL has purchased 1,024,288 shares of Immunocore (NASDAQ:IMCR) in Q2, valuing its stake at $32.14 million and representing 2.04% ownership. Immunocore, a commercial-stage biotechnology company, reported an EPS beat but a revenue miss in its latest quarter, with analysts maintaining a "Moderate Buy" consensus rating and a $61 average price target. Institutional investors hold a significant 84.5% of the company's stock.
